Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11739MR)

This product GTTS-WQ11739MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ11739MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11466MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ9912MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ9231MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ10574MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ5002MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ8722MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ7966MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ3696MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 2287409
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW